214 related articles for article (PubMed ID: 34032019)
1. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
3. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
4. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
Mills KR; Misra J; Torabifard H
J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
[TBL] [Abstract][Full Text] [Related]
5. Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
Mélin L; Abdullayev S; Fnaiche A; Vu V; González Suárez N; Zeng H; Szewczyk MM; Li F; Senisterra G; Allali-Hassani A; Chau I; Dong A; Woo S; Annabi B; Halabelian L; LaPlante SR; Vedadi M; Barsyte-Lovejoy D; Santhakumar V; Gagnon A
ChemMedChem; 2021 Oct; 16(19):2982-3002. PubMed ID: 34164919
[TBL] [Abstract][Full Text] [Related]
6. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
Zagiel B; Melnyk P; Cotelle P
Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
[TBL] [Abstract][Full Text] [Related]
8. Mechanosignaling YAP/TAZ-TEAD Axis Regulates the Immunomodulatory Properties of Mesenchymal Stem Cells.
Yoshii H; Kajiya M; Yoshino M; Morimoto S; Horikoshi S; Tari M; Motoike S; Iwata T; Ouhara K; Ando T; Yoshimoto T; Shintani T; Mizuno N
Stem Cell Rev Rep; 2024 Jan; 20(1):347-361. PubMed ID: 37917410
[TBL] [Abstract][Full Text] [Related]
9. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
[TBL] [Abstract][Full Text] [Related]
10. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
11. Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer.
Iftikhar R; Zahoor AF; Irfan M; Rasul A; Rao F
Chem Biol Drug Des; 2021 Dec; 98(6):1025-1037. PubMed ID: 34587361
[TBL] [Abstract][Full Text] [Related]
12. Yap/Taz inhibit goblet cell fate to maintain lung epithelial homeostasis.
Hicks-Berthet J; Ning B; Federico A; Tilston-Lunel A; Matschulat A; Ai X; Lenburg ME; Beane J; Monti S; Varelas X
Cell Rep; 2021 Jul; 36(2):109347. PubMed ID: 34260916
[TBL] [Abstract][Full Text] [Related]
13. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
Laraba L; Hillson L; de Guibert JG; Hewitt A; Jaques MR; Tang TT; Post L; Ercolano E; Rai G; Yang SM; Jagger DJ; Woznica W; Edwards P; Shivane AG; Hanemann CO; Parkinson DB
Brain; 2023 Apr; 146(4):1697-1713. PubMed ID: 36148553
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options.
Strepkos D; Markouli M; Papavassiliou KA; Papavassiliou AG; Piperi C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12762. PubMed ID: 34409639
[TBL] [Abstract][Full Text] [Related]
17. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.
Guo Y; Zhu Z; Huang Z; Cui L; Yu W; Hong W; Zhou Z; Du P; Liu CY
Nat Commun; 2022 Aug; 13(1):4995. PubMed ID: 36008411
[TBL] [Abstract][Full Text] [Related]
18. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
19. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]